Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs partner to bring PrecisionCHD test to India, aiming to address high heart ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

Shares of Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) climbed about 9.3% in premarket trading on Wednesday after the company unveiled plans to expand into India, marking its first move beyond the U.

An AI-powered heart disease test from Chicago firm is expanding to its first international market. Learn more here.

The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its ...

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...

One of the strongest predictors of long-term mortality among patients undergoing a cardiac stress test is the need for a pharmacologic versus treadmill test, new data show. Moreover, although the risk ...

This surprisingly simple walking test is becoming a go-to tool for measuring real cardiovascular fitness—no gym, no gadgets, ...